Autopsy report · NCT00212017

Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT

“We obtained the final results due to the interim analysis.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 12 years 4 months before it stopped.
• 3,000 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

National Cerebral and Cardiovascular Center, Japan

Sponsor type

University, hospital or other

Conditions

Impaired Glucose Tolerance; Myocardial Infarction

Interventions

voglibose; diet and exercise therapy

Participants

3,000

Sites

1

Countries

Japan

Trials that died the same way

• Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
  “The study is closed per results from the interim analysis.” (73% match in meaning)
• Liberty Analyzer WBC System: Reference Interval Study
  “For interim analysis.” (68% match in meaning)
• Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
  “Pending Interim Analysis” (67% match in meaning)
• EUS-CNB Versus EUS-SINK for Diagnosis of Upper Gastrointestinal (UGI) Subepithelial Tumors
  “Equality of results between the two groups at interim analysis” (67% match in meaning)
• Verapamil vs Steroid to Prevent Keloid Recurrence
  “Objective of study achieved after interim analysis.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.